New biologic bests methotrexate in RA
A newly FDA-approved JAK inhibitor is more effective than methotrexate for treating rheumatoid arthritis, according to a two-year study published in the New England Journal of Medicine.
It shows patients on oral tofacitinib monotherapy are significantly more likely than those on methotrexate to display an American College of Rheumatology (ACR) 70 response.
The best improvements after six months were for patients receiving 10mg twice a day, 38% of whom had an ACR 70 response. This compares with 25% of those on 5mg twice a day and 12% of